Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 48,484
Open 17.94
Bid (Size) 18.00 (100)
Ask (Size) 18.27 (10)
Prev. Close 17.94
Today's Range 17.94 - 17.94
52wk Range 10.41 - 144.22
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
SAREPTA (SRPT) LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-85.5%
-85.5%
1 Month
-6.7%
-6.7%
3 Month
-50.7%
-50.7%
6 Month
-84.1%
-84.1%
1 Year
-86.1%
-86.1%

More News

Read More
Shareholders That Lost Money on Sarepta Therapeutics, Inc. (SRPT) Should Contact Levi & Korsinsky About Pending Class Action - SRPT
Via NewMediaWire
Topics Fraud Lawsuit
This Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity
Via Stocktwits
Earnings Scheduled For August 6, 2025
Via Benzinga
What to Expect from Sarepta Therapeutics's Earnings
Via Benzinga
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Via Benzinga
C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
From Bernstein Liebhard LLP
Via GlobeNewswire
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Trump Ally Laura Loomer Calls Vinay Prasad A ‘Marxist Trojan Horse’ After FDA Rehiring, Slams NASA For Dropping Isaacman
Via Stocktwits
Topics Death Government
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via NewMediaWire
Topics Fraud Lawsuit
SRPT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
What 43 Analyst Ratings Have To Say About Sarepta Therapeutics
Via Benzinga
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via NewMediaWire
Topics Fraud Lawsuit
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via TheNewswire.com
Topics Fraud Lawsuit
Dow Futures Rise As Trump’s Reciprocal Tariff Deadline Kicks In: AAPL, NVDA, INTC, LLY, SRPT Among Stocks To Watch
Via Stocktwits
Topics Government Stocks
Sarepta Therapeutics Inc (NASDAQ:SRPT) Surpasses Q2 2025 Estimates with Strong ELEVIDYS Performance
Via Chartmill
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via NewMediaWire
Topics Fraud Lawsuit
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 17.94
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 08/11/25 04:00 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.67B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.